A Systematic Review of Ocular Complications Following Different Types of Covid-19 Vaccines.

Publisher: Wiley Country of Publication: Egypt NLM ID: 101627166 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-7156 (Electronic) Linking ISSN: 23147156 NLM ISO Abbreviation: J Immunol Res Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: Cairo, Egypt : Hindawi Publishing Corporation, [2014]-

COVID-19*/prevention & control ; COVID-19*/immunology ; COVID-19 Vaccines*/adverse effects ; Eye Diseases*/etiology ; SARS-CoV-2*/immunology ; Uveitis*/etiology ; Uveitis*/epidemiology; Humans ; Risk Factors ; Vaccination/adverse effects

Introduction: More than 6 million deaths from the novel coronavirus, the Coronavirus disease 2019 (COVID-19) infection, have prompted the development of several prophylactic vaccines of COVID-19. This systematic review summarizes the ocular complications of various COVID-19 vaccinations, diseases diagnosed, treatment, and risk factors.
Methods: The search was done in PubMed, Web of Science (WOS), and Google Scholar databases. Manifestations were classified depending on the type of vaccines and the interval between vaccination and the onset of symptoms. Other data such as patients' age, gender, underlying diseases, and follow-up data were also extracted.
Results: Initially, 10,242 articles were identified and 76 articles were eligible that among them 107 cases were reported. Ocular complications were diagnosed more often in Pfizer-BioNTech COVID-19 vaccine and Oxford-AstraZeneca COVID-19 vaccine (AstraZeneca) recipients than in others.
Conclusion: This systematic review highlights a wide range of ocular complications reported after COVID-19 vaccination, the most common of which is uveitis. While most cases were mild and self-limiting, some involved reactivation of preexisting inflammatory diseases. These findings emphasize the importance of postvaccination ocular surveillance. This is particularly important in individuals with a history of ocular inflammation and suggests a potential immunological mechanism that requires further investigation.
(Copyright © 2025 Bahareh Ebrahimi et al. Journal of Immunology Research published by John Wiley & Sons Ltd.)

The authors declare no conflicts of interest.

Cureus. 2022 Mar 26;14(3):e23526. (PMID: 35494952)
Ocul Immunol Inflamm. 2023 Aug;31(6):1141-1144. (PMID: 35914301)
BMC Neurol. 2022 Feb 12;22(1):54. (PMID: 35151258)
Doc Ophthalmol. 2022 Aug;145(1):65-70. (PMID: 35763179)
BMJ Case Rep. 2021 Sep 7;14(9):. (PMID: 34493563)
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23751-23761. (PMID: 32917815)
Vaccines (Basel). 2023 Mar 24;11(4):. (PMID: 37112636)
Photodiagnosis Photodyn Ther. 2021 Sep;35:102406. (PMID: 34144260)
Ocul Immunol Inflamm. 2021 May 19;29(4):753-757. (PMID: 34344280)
Hum Vaccin Immunother. 2022 Nov 30;18(5):2090177. (PMID: 35731625)
Cureus. 2022 Jul 31;14(7):e27502. (PMID: 36060339)
Am J Ophthalmol Case Rep. 2022 Sep;27:101592. (PMID: 35642221)
Am J Ophthalmol Case Rep. 2022 Jun;26:101430. (PMID: 35198832)
Lancet Infect Dis. 2021 Jul;21(7):939-949. (PMID: 33930320)
Front Pharmacol. 2022 Mar 24;13:845615. (PMID: 35401231)
Vaccines (Basel). 2022 Jan 13;10(1):. (PMID: 35062778)
Indian J Ophthalmol. 2022 May;70(5):1817-1818. (PMID: 35502082)
Indian J Ophthalmol. 2021 Oct;69(10):2865-2866. (PMID: 34571653)
Ophthalmol Ther. 2022 Feb;11(1):453-458. (PMID: 34881416)
Eur J Ophthalmol. 2023 Sep;33(5):NP29-NP34. (PMID: 36062603)
Am J Case Rep. 2022 Mar 27;23:e935095. (PMID: 35340016)
Vaccines (Basel). 2022 Oct 20;10(10):. (PMID: 36298623)
Health Sci Rep. 2022 Feb 15;5(2):e510. (PMID: 35224216)
Case Rep Ophthalmol Med. 2022 May 19;2022:7094893. (PMID: 35601874)
Front Immunol. 2018 Aug 27;9:1931. (PMID: 30210492)
Case Rep Ophthalmol. 2022 Mar 4;13(1):124-127. (PMID: 35431883)
Ocul Immunol Inflamm. 2023 Apr;31(3):609-612. (PMID: 35133925)
Mol Ther. 2022 May 4;30(5):1850-1868. (PMID: 35189345)
Am J Ophthalmol Case Rep. 2021 Dec;24:101207. (PMID: 34580648)
Cornea. 2021 Aug 1;40(8):1070-1072. (PMID: 34029238)
Front Med (Lausanne). 2022 Oct 26;9:999251. (PMID: 36388944)
Front Public Health. 2022 Mar 14;10:834744. (PMID: 35359754)
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1200-1206. (PMID: 34402726)
Vaccines (Basel). 2023 Mar 17;11(3):. (PMID: 36992266)
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1207-1209. (PMID: 34379565)
J Ophthalmic Vis Res. 2021 Jan 20;16(1):103-112. (PMID: 33520133)
Vaccines (Basel). 2022 Feb 21;10(2):. (PMID: 35214800)
Front Immunol. 2021 Aug 31;12:720952. (PMID: 34531867)
Int J Infect Dis. 2021 Sep;110:95-97. (PMID: 34289406)
Am J Ophthalmol Case Rep. 2022 Sep;27:101654. (PMID: 35818371)
Indian J Ophthalmol. 2022 Oct;70(10):3716-3718. (PMID: 36190081)
EClinicalMedicine. 2021 Aug;38:100989. (PMID: 34222848)
JAMA. 2021 Jun 1;325(21):2201-2202. (PMID: 33818592)
Can J Ophthalmol. 2023 Jun;58(3):e122-e124. (PMID: 36288774)
J Med Virol. 2022 Jul;94(7):2939-2961. (PMID: 35229324)
Int J Infect Dis. 2021 Dec;113:116-118. (PMID: 34601147)
Front Immunol. 2012 Jun 19;3:169. (PMID: 22723800)
Vaccines (Basel). 2023 Feb 05;11(2):. (PMID: 36851242)
Ocul Immunol Inflamm. 2022 Jul;30(5):1133-1135. (PMID: 34851795)
Am J Ophthalmol Case Rep. 2022 Jun 11;27:101616. (PMID: 35719316)
Front Immunol. 2018 Apr 17;9:794. (PMID: 29755457)
Vaccines (Basel). 2022 Sep 03;10(9):. (PMID: 36146540)
J Infect. 2022 Jan;84(1):94-118. (PMID: 34332017)
J Fr Ophtalmol. 2022 Sep;45(7):e306-e308. (PMID: 35643738)
Arq Bras Oftalmol. 2022 Jan 21;85(2):186-189. (PMID: 35298582)
Eye Contact Lens. 2021 Nov 1;47(11):625-628. (PMID: 34516456)
Medicine (Baltimore). 2021 Dec 17;100(50):e28236. (PMID: 34918688)
Signal Transduct Target Ther. 2023 Sep 20;8(1):365. (PMID: 37726283)
JAMA Ophthalmol. 2021 Oct 1;139(10):1135-1136. (PMID: 34473193)
J Ophthalmic Vis Res. 2021 Jul 29;16(3):490-501. (PMID: 34394876)
Am J Ophthalmol Case Rep. 2022 Sep;27:101644. (PMID: 35818570)
Ocul Immunol Inflamm. 2023 Jan;31(1):233-235. (PMID: 34802376)
Ocul Immunol Inflamm. 2022 Jul;30(5):1255-1259. (PMID: 35404749)
Ocul Immunol Inflamm. 2022 Jul;30(5):1278-1281. (PMID: 35442848)
Int Med Case Rep J. 2022 Jan 16;15:7-14. (PMID: 35079224)
J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):4. (PMID: 34982290)
BMJ Case Rep. 2022 May 13;15(5):. (PMID: 35568418)
Ocul Immunol Inflamm. 2022 Jul;30(5):1274-1277. (PMID: 35412946)
Clin Exp Vaccine Res. 2021 Sep;10(3):264-275. (PMID: 34703810)
Vaccine. 2021 Oct 22;39(44):6492-6509. (PMID: 34600747)
Ocul Immunol Inflamm. 2021 May 19;29(4):730-733. (PMID: 34187278)
Ocul Immunol Inflamm. 2022 Jul;30(5):1214-1217. (PMID: 34797736)
Medicine (Baltimore). 2022 Jul 22;101(29):e30041. (PMID: 35866821)
Int J Retina Vitreous. 2022 Jun 20;8(1):43. (PMID: 35725633)
Vaccines (Basel). 2023 Nov 21;11(12):. (PMID: 38140142)
Vaccines (Basel). 2022 Feb 25;10(3):. (PMID: 35334994)
Indian J Ophthalmol. 2021 Oct;69(10):2862-2864. (PMID: 34571652)
Clin Case Rep. 2022 Jun 07;10(6):e05926. (PMID: 35685829)
Cureus. 2022 Jan 5;14(1):e20967. (PMID: 35154946)
Pharm Pract (Granada). 2022 Apr-Jun;20(2):2678. (PMID: 35919795)
Case Rep Ophthalmol. 2022 Jul 15;13(2):562-569. (PMID: 36160489)
Am J Ophthalmol Case Rep. 2021 Dec;24:101212. (PMID: 34580649)
Hum Vaccin Immunother. 2022 Nov 30;18(5):2043719. (PMID: 35318872)
Ocul Immunol Inflamm. 2023 Aug;31(6):1222-1225. (PMID: 35914286)
Vaccines (Basel). 2022 Nov 09;10(11):. (PMID: 36366396)
Nat Hum Behav. 2021 Jul;5(7):947-953. (PMID: 33972767)
Infect Disord Drug Targets. 2022;22(5):e290921196908. (PMID: 34587889)
Medicine (Baltimore). 2022 Jan 14;101(2):e28582. (PMID: 35029236)
Am J Infect Control. 2022 Jan;50(1):15-19. (PMID: 34699960)
Asian J Psychiatr. 2022 May;71:103129. (PMID: 35447503)
Trends Cardiovasc Med. 2022 Jul;32(5):249-256. (PMID: 35202800)
J Emerg Med. 2021 Dec;61(6):e146-e150. (PMID: 34690021)
N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794)
Cureus. 2022 Jun 11;14(6):e25842. (PMID: 35832754)
Front Immunol. 2020 Jun 16;11:1441. (PMID: 32612615)
Retin Cases Brief Rep. 2023 Jul 1;17(4):441-444. (PMID: 35025191)
Arch Acad Emerg Med. 2022 Jul 4;10(1):e53. (PMID: 36033989)
J Neurol. 2022 Mar;269(3):1093-1106. (PMID: 34480607)
Vaccines (Basel). 2022 Jun 09;10(6):. (PMID: 35746527)
Am J Ophthalmol Case Rep. 2022 Jun;26:101445. (PMID: 35211659)
Vaccines (Basel). 2021 Nov 17;9(11):. (PMID: 34835280)
Inflamm Res. 2021 Sep;70(9):931-933. (PMID: 34086060)
BMC Infect Dis. 2023 Jan 5;23(1):5. (PMID: 36604613)
Case Rep Ophthalmol. 2022 Oct 11;13(3):789-792. (PMID: 36845447)
SAGE Open Med. 2022 Jul 6;10:20503121221108616. (PMID: 35832260)
Int Med Case Rep J. 2022 Apr 14;15:201-204. (PMID: 35444474)
Vaccines (Basel). 2023 May 31;11(6):. (PMID: 37376434)
EClinicalMedicine. 2022 Aug 27;53:101624. (PMID: 36051247)
Eye (Lond). 2022 Jun;36(6):1319-1320. (PMID: 34426655)
Arch Acad Emerg Med. 2022 Sep 24;10(1):e76. (PMID: 36426163)
Am J Ophthalmol Case Rep. 2021 Dec;24:101200. (PMID: 34485760)
Case Rep Ophthalmol Med. 2021 Oct 14;2021:5126254. (PMID: 34659851)
Lancet Reg Health Eur. 2021 Feb;1:100012. (PMID: 33954296)
Arch Pathol Lab Med. 2022 Jun 1;146(6):677-685. (PMID: 35188563)
Virusdisease. 2022 Mar;33(1):1-22. (PMID: 35127995)
Clin Ophthalmol. 2022 Mar 31;16:987-992. (PMID: 35392428)
Virol J. 2022 Jun 5;19(1):100. (PMID: 35659687)
Ther Adv Ophthalmol. 2022 Apr 12;14:25158414221083374. (PMID: 35434520)
Vaccines (Basel). 2023 Oct 23;11(10):. (PMID: 37897028)
Ocul Immunol Inflamm. 2022 Jul;30(5):1240-1243. (PMID: 35201960)
J Clin Med. 2021 Dec 19;10(24):. (PMID: 34945256)
Ophthalmic Plast Reconstr Surg. 2022 May-Jun 01;38(3):e67-e70. (PMID: 35323144)
Am J Ophthalmol Case Rep. 2022 Jun;26:101479. (PMID: 35282606)
Crit Rev Clin Lab Sci. 2022 Sep;59(6):373-390. (PMID: 35220860)
Am J Ophthalmol Case Rep. 2022 Jun;26:101532. (PMID: 35434421)
Vaccines (Basel). 2022 Jun 10;10(6):. (PMID: 35746538)
BMJ Open. 2022 Feb 24;12(2):e050278. (PMID: 35210336)
Am J Ophthalmol Case Rep. 2022 Mar;25:101281. (PMID: 35075438)
Case Rep Ophthalmol. 2022 Jan 31;13(1):28-32. (PMID: 35221977)
Front Immunol. 2019 May 09;10:1076. (PMID: 31156632)

Keywords: BNT162 vaccine; COVID-19 vaccine; ChadOx1 nCoV-19; coronavirus; eye diseases; mRNA vaccines

0 (COVID-19 Vaccines)

Date Created: 20251023 Date Completed: 20251023 Latest Revision: 20251124

20251125

PMC12538234

10.1155/jimr/8766021

41127248